This Phase 2, single center, open-label research study is studying the combination of Anakinra and Axicabtagene Ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities in people with relapsed or refractory Non-Hodgkin lymphoma (NHL).~The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.~This research study involves two drugs:~Anakinra~Axicabtagene Ciloleucel~A total of 20 participants will be enrolled to this trial~The U.S. Food and Drug Administration (FDA) has not approved anakinra for use in treatment of Non-Hodgkin lymphoma (NHL).
This research study is studying the combination of anakinra and axicabtagene ciloleucel to reduce the occurrence of the side effects Cytokine Release Syndrome (CRS) and neurologic toxicities with relapsed or refractory Non-Hodgkin lymphoma (NHL).~Relapsed NHL is the condition of returned Non-Hodgkin lymphoma.~Refractory NHL is the condition of previous treatment resistant Non-Hodgkin lymphoma.~Cytokine Release Syndrome (CRS) is a group of side effect symptoms that can include nausea, headache, rapid heartbeat, shortness of breath, kidney damage, and rash.~Neurologic toxicity is nervous system disorder characterized by confusion~This research study involves two drugs:~Anakinra~Axicabtagene Ciloleucel.